Clinical Trials Logo

Ewing Sarcoma of Bone clinical trials

View clinical trials related to Ewing Sarcoma of Bone.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05116800 Withdrawn - Soft Tissue Sarcoma Clinical Trials

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Start date: March 1, 2022
Phase: Phase 2
Study type: Interventional

This is an open label, two-stratum, phase 2 clinical trial evaluating the efficacy of 9-ING-41 in combination with gemcitabine/docetaxel in patients ≥10 years of age with advanced sarcoma. 9-ING-41 in combination with gemcitabine and docetaxel will lead to sustained disease control and/or increase the rates of objective response in patients with unresectable or metastatic soft tissue and bone sarcomas.

NCT ID: NCT01795430 Withdrawn - Clinical trials for Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma

Start date: July 2013
Phase: N/A
Study type: Interventional

This pilot clinical trial studies whole-body radiation therapy, systemic chemotherapy, and high-dose chemotherapy followed by stem cell rescue in treating patients with poor-risk Ewing sarcoma. Giving chemotherapy and radiation therapy before a peripheral blood stem cell or bone marrow transplant stops the growth of tumor cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is given to prepare the bone marrow for stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy